Results of [131I]metaiodobenzylguanidine treatment in metastatic malignant phaeochromocytoma.
The results obtained with [131I]metaiodobenzylguanidine (131I-MIBG) treatment in 6 patients affected by metastatic phaeochromocytoma are reported. Single doses of 3.7-7.4 GBq were given, in 1-6 courses, up to cumulative doses of 5.4-37.8 GBq. Objective responses were observed in 5 patients (2 tumour shrinkages, even if small; 5 lowering of blood pressure), which were only temporary in 3 patients and stable in 2. Complete disappearance of pain was obtained in 2/2 patients. No adverse side-effects were observed. The problem of treatment strategy in situations of stable disease deserves further study.
Bestagno
M
M
Nuclear Medicine Service, Spedali Civili, Brescia, Italy.
Pizzocaro
C
C
Maira
G
G
Terzi
A
A
Panarotto
M B
MB
Guerra
P
P
D019797:3-Iodobenzylguanidine; D000310:Adrenal Gland Neoplasms / Q000628:therapy*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D007462:Iodobenzenes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010673:Pheochromocytoma / Q000556:secondary* / Q000628:therapy
D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine